(12) International Application Status Report

Received at International Bureau: 09 August 2018 (09.08.2018)

Information valid as of: 22 January 2019 (22.01.2019)

Report generated on: 23 September 2019 (23.09.2019)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2019/03015614 February 2019 (14.02.2019) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/EP2018/07123206 August 2018 (06.08.2018) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
PCTEP2017069976 (EP)07 August 2017 (07.08.2017) Priority document received (in compliance with PCT Rule 17.1)
18154731.6 (EP)01 February 2018 (01.02.2018) Priority document received (in compliance with PCT Rule 17.1)
18163964.2 (EP)26 March 2018 (26.03.2018) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07K 14/31 (2006.01); B01D 15/38 (2006.01); B01J 20/289 (2006.01)

(71) Applicant(s):
REPLIGEN CORPORATION [--/US]; 41 Seyon Street Waltham, Massachusetts 02453 (US) (for all designated states)

(72) Inventor(s):
FIEDLER, Erik; Navigo Proteins GmbH Heinrich Damerow Str. 1 06120 Halle/Saale (DE)
HAUPTS, Ulrich; Navigo Proteins GmbH Heinrich Damerow Str. 1 06120 Halle/Saale (DE)

(74) Agent(s):
ARNOLD & SIEDSMA B.V.; P.O. Box 18558 2502 EN The Hague (NL)

(54) Title (EN): FC BINDING PROTEINS WITH CYSTEINE IN THE C-TERMINAL HELICAL REGION
(54) Title (FR): PROTÉINES DE LIAISON FC AVEC LA CYSTÉINE DANS LA RÉGION HÉLICOÏDALE C-TERMINALE

(57) Abstract:
(EN): The present invention relates to Fc binding proteins comprising one or more domains with Cysteine in the C-terminal helical region. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.
(FR): La présente invention concerne des protéines de liaison Fc, comprenant un ou plusieurs domaines, avec la cystéine dans la région hélicoïdale C-terminale. L'invention concerne en outre des matrices d'affinité comprenant les protéines de liaison Fc de l'invention. L'invention concerne également l'utilisation de ces protéines de liaison Fc ou de matrices d'affinité pour la purification par affinité d'immunoglobulines, ainsi que des procédés de purification par affinité à l'aide des protéines de liaison Fc de l'invention.

International search report:
Received at International Bureau: 18 September 2018 (18.09.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM